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Abstract
Background: Pregnancy in Type 1 diabetic patients is a precarious condition, both for mother and
fetus with increased the risk of prematurity and, immediately after delivery with risk of respiratory
distress syndrome and hypoglycaemia in newborns. A strict control and monitoring of diabetes
throughout pregnancy is important in reducing the impact of the disease on the fetus and newborn.
In recent years many new technologies have been introduced to ameliorate diabetes monitoring,
where the last is the Real-time Continuous Glucose Monitoring System (RT-CGMS).
Methods:  In the last three years, 72 h continuous glucose monitoring system (RT-CGMS)
(Medtronic, CA) was performed in 18 pregnant women with Type 1 diabetes in two moments of
pregnancy: during treatment with betamethasone to prevent respiratory distress and during
delivery. In both cases insulin was administered intravenous and the dose was changed on the basis
of glycaemia.
Results:  The results present the use of this new technique during two topics moments of
pregnancy of type 1 diabetes patients when is very important intensively to monitor diabetes and
to obtain the well being of the fetus. No infant experimented hypoglycaemia or respiratory distress
syndrome at the moment and in the first hours after the birth.
Conclusion: We wish to stress the importance reducing glycaemia during administration of
betamethasone and during labor. It is conceivable that the scarce attention paid to monitoring
glucose levels in diabetic mothers during labor in gynaecological world may be due to the difficulty
in glucose monitoring with the devices until now available. Hopefully, our anecdotal account may
prompt improvements with RT-CGMS, and may lead to a better approach to the problem, thereby
changing the prognosis of infants born to diabetic mothers.
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Background
Infants born to type 1 diabetic mothers are at significantly
greater risk for perinatal morbidity. Two conditions are
very frequent at the birth: respiratory distress syndrome
(RDS) and hypoglycaemia. Strict maternal glycemic con-
trol during pregnancy complicated by diabetes mellitus
reduces neonatal morbidity and mortality.
Respiratory Distress Syndrome
Infants of type 1 diabetic mothers are more likely to have
respiratory symptoms in the newborn period from either
RDS (surfactant deficiency) or retained fetal lung fluid
(transient tachypnea of the newborn) after operative
delivery.[1]. RDS occurs more frequently in IDMs (Infants
of Diabetic Mother) because of later onset of maturity of
the type II alveolar cells[2] and is secondary to pulmonary
surfactant deficiency. Fetal hyperinsulinism is a key factor
in the pathogenesis of RDS because insulin is believed to
antagonize the physiological maturing effect of cortisol.
[3]. Hyperinsulinism is also responsible for polycythemia,
a condition inducing persistent pulmonary hypertension
which complicates the course of RDS.
Ideally, RDS is prevented by excellent maternal glycemic
control during pregnancy [2]. Corticosteroids are strongly
recommended to prevent prematurity complications in
newborns of non-diabetic mothers in whom a rise in
blood glucose levels in the two days following administra-
tion of betamethasone has been reported [4]. Due to the
higher risk of RDS in infants from diabetic mothers
administration of betamethasone to the mother is even
more advisable then in non-diabetic mothers. On the
other side the consequent rise in blood glucose levels [4]
is expected to be more marked in diabetic than in non-
diabetic mothers thus requiring a strict adjustment of the
insulin therapy. This because the fetal hyperinsulinism
consequent to the maternal hyperglycemic peak could
block the beneficial effect of the administered betametha-
sone on fetal pulmonary maturation.
Hypoglycaemia
In the diabetic pregnant the stress during the labour usu-
ally induces a further increase of blood glucose levels with
a consequent rise of the fetal production of insulin and
increased risk of hypoglycemia. Therefore, a close moni-
toring of blood glucose in the mother together with an
appropriate insulin treatment during the last hours before
delivery are needed.
Over the past years practitioners have sought to improve
the outcome of diabetic pregnancies. In pregnancies com-
plicated by type 1 diabetes, where excellent glucose con-
trol is desired to improve maternal and fetal outcomes,
RT-CGMS, a novel well tolerated tool to assess 24-h glu-
cose fluctuations, may have a role in fine-tuning manage-
ment [5]. Its role may be crucial in two topic moments of
pregnancy such as betamethasone therapy and labor.
Methods
Eighteen pregnant women (mean age 23.4 ± 2.5 yrs; range
18–28 yrs) with type 1 diabetes (mean age at the diagnosis
8.5 ± 3.3 yrs; mean duration of the disease 14.8 ± 2.9 yrs)
were consecutively enrolled in the study in the last 3 years
(2004–2007).
The research plan has been approved by the Ethics Com-
mittee of Department of Pediatrics of the Second Univer-
sity of Naples. An informed consent was signed by all
mothers taking part to the study.
All patients wore Real Time Continuous Glucose Monitor-
ing System sensors (RT-CGMS), in two moments: during
treatment with betamethasone and in the perinatal period
and during labor. The glycemic profile was obtained with
a continuous glucose monitoring system, not equipped
for real-time visualization of the results (CGMS
Medtronic), in the first 4 patients at the beginning of the
study and with a Guardian® Real Time CGMS (Medtronic)
equipped for real-time visualization of the results in the
others.
The CGMS unit consists of a glucose sensor, which is
inserted into the subcutaneous tissue of the body and left
in place for up to 72 hours. This sensor senses the intersti-
tial fluid glucose levels electrochemically every 10 sec-
onds, records an average value every 5 minutes and gives
288 values per day. The sensor of CGMS after 72 hours is
removed and the data from the monitor are downloaded
into a PC, which gives a continuous graph of the glucose
values of the previous 3 days; Guardian® Real Time CGMS
(Medtronic) uses a continuous telemetry display of real-
time glucose values.
The RT-CGMS is an accurate tool for additional glucose
monitoring in pregnant women with type 1 diabetes mel-
litus as previously demonstrated [6].
Betamethasone was administered intramuscularly (12
mg/24 h for two days) between the 30th and 32nd week of
gestation.
Continuous intravenous infusion of insulin (between
0.02 U/kg/h and 0.06 U/kg/h), guided by glucose levels,
enabled us to reach and maintain glucose levels constant
between 100 and 150 mg/dl during treatment with beta-
methasone and during labor up to delivery in the vaginal
delivery and between 80 and 100 mg/dl during the caesar-
ean section birth.BMC Pregnancy and Childbirth 2008, 8:23 http://www.biomedcentral.com/1471-2393/8/23
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Continuous Graph of the glucose values of 3 days Figure 1
Continuous Graph of the glucose values of 3 days.
A
DM Stefania age  25 years, vaginal delivery, duration of gestation 32 weeks.  
Infant birth weight kg 1.620 (50° pc), glycaemia at birth 56 mg/dl. No hypoglycaemic episodes during the first 72 hrs after birth
B
P Patrizia age 28 years, vaginal delivery, duration of gestation38 weeks  
Infant birth weight kg 4.100 (97° pc),  glycaemia at the birth 53 mg/dl.  
No hypoglycaemic episodes during the first 72 hrs after birth  
C
21/09/2006 22/09/2006 23/09/2006 20/09/2006 
DM Daniela age 28 yrs caesarean delivery 34 weeks of gestation  
Infant birth weight kg 3.520 (97° pc), glycaemia at the birth 50 mg/dl.  
No hypoglycaemic episodes during the first 72 hrs after birth  
D
N. Marianna age 30 yrs  
33 weeks of gestation
E
C. Cristina age 28 yrs 
32 weeks of gestation
Figure legend
Labor              Insulin i.v .                     Betamethasone 12 mg i.m. 
On the x-axis are hours and every graph is a day. On the y-axis are glycemic values (mg/dl)
° The circle symbols represent glycaemia at the finger. BMC Pregnancy and Childbirth 2008, 8:23 http://www.biomedcentral.com/1471-2393/8/23
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Results and Discussion
At the beginning of the study after betamethasone admin-
istration we tried to maintain the multi-injection insulin
therapy but it did not prevent an increase of glycaemia
despite of the increasing insulin dose.
Fig 1D shows the continuous graph of the glucose values
of a patient who received, the day after betamethasone,
multi-injection insulin therapy at a dose of 0,9 Units/Kg/
day in 4 administrations/day, which did not prevent an
increase of glycaemia monitored for about 24 h (around
200 mg/dl with a peak of 250 mg/dl after 15 h). After the
second betamethasone injection, intravenous insulin was
introduced reducing the degree and duration of hypergly-
caemic peaks (<200 mg/dl).
Fig. 1E shows the graph of the first patient in which intra-
venous insulin was introduced after the first betametha-
sone dose resulting in an acceptable level of glycaemia
from the beginning and for all two days of treatment.
We wish to stress the importance of reducing glycaemia
and keeping blood glucose under tight control during
administration of betamethasone not only for the meta-
bolic status of the mother but to avoid hyperinsulinism of
fetus that block the beneficial effect of betamethasone on
pulmonary maturation.
No newborn from mothers of our study developed Respi-
ratory Distress Syndrome after the birth.
Another period of high risk for babies from type 1 diabetic
mothers is during delivery, when hyperglycaemia could
induce the newborns to produce high amounts of insulin
with the consequence of hypoglycaemic status after the
cut of the blood cord.
The profile in Figure 1A, obtained with a continuous glu-
cose monitoring system (CGMS®; Medtronic USA) not
equipped for real-time visualization of the results, shows
that rapid, prolonged hyperglycaemia can occur during
labor and has provided opportunities to examine limita-
tions of conventional monitoring of glycaemia by inter-
mittent finger-stick testing.
Figure 1B and 1C (vaginal delivery and caesarean section)
obtained with a Guardian® Real Time CGMS (Medtronic)
equipped for real-time visualization of the results shows
that the continuous infusion of insulin (between 0.02 U/
kg/h and 0.06 U/kg/h), guided by glucose levels, enabled
us to reach and maintain glucose levels constant between
100 and 150 mg/dl during labor up to the vaginal delivery
and between 80 and 100 mg/dl during the caesarean sec-
tion birth.
The mean glycemic values of infants immediately after
birth was 84 ± 16 mg/dl and no hypoglycaemic episode
was recorded during the first 72 hrs after birth.
Conclusion
Real-time CGMS is a very useful tool for obstetrics and
diabetologists during the follow up of the pregnant type 1
diabetic patients in particular when the objective of the
therapy is euglycaemia. The sensor is useful because it per-
mits a closer observation of the fluctuation of blood glu-
cose levels. It would be impossible to measure blood
glucose on capillary blood at the same frequency intervals
mainly for the discomfort of the repeated punctures.
Therefore, we wish to stress the importance of reducing
glycaemia during administration of betamethasone and
during the labor. It is conceivable that the scarce attention
paid to monitoring glucose levels in diabetic mothers dur-
ing labour in gynaecological worlds may be due to the dif-
ficulty in glucose monitoring with the traditional devices
until now available. Hopefully, our anecdotal account
may prompt improvements in CGMS, and may lead to a
better approach to the problem, thereby changing the
prognosis of infants born to diabetic mothers.
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